FUNDAMENTALS · Fundamentals · CN Healthcare

Yidu Tech (2158) Fundamentals 2026 — P/E 63.5x, Revenue Analysis | SniperIQ

Yidu Tech (2158) is a CN-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of HK$4.9B, trading at HK$4.83 on the HKSE. This SniperIQ fundamentals page covers Yidu Tech's valuation (P/E 63.5x, P/B 1.2x), profitability (net margin 8.7%), revenue (¥791M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK$4.9B
P/E (TTM)63.5x
Net Margin8.7%
Revenue (FY25)¥791M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Yidu Tech's market cap?

Yidu Tech (2158) has a market capitalization of approximately HK$4.9B, trading at HK$4.83 on the HKSE. Market cap moves with the live share price.

What is Yidu Tech's P/E ratio?

Yidu Tech's trailing twelve-month P/E ratio is 63.5x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Yidu Tech?

Yidu Tech runs a net profit margin of 8.7%, a gross margin of 36.4%, and an operating margin of 1.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Yidu Tech generate?

Yidu Tech reported revenue of ¥791M for fiscal year 2025, with net income of ¥70M and earnings per share (EPS) of 0.0669. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Yidu Tech pay a dividend?

Yidu Tech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Yidu Tech financially healthy?

Yidu Tech carries a debt-to-equity ratio of 0.02x and a current ratio of 4.81x, with a market beta of 1.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Yidu Tech a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yidu Tech (2158) the key facts are: market cap HK$4.9B, P/E 63.5x, revenue ¥791M, 52-week range 4.05-7.24. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Yidu Tech's full fundamentals live

Get Yidu Tech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Sotera Health (SHC) fundamentals · Jiangsu Jibeier Pharmaceutical (688566) fundamentals · Indivior Pharmaceuticals (INDV) fundamentals · National Medical Care (4005) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons